41844-91-1

Usage

Uses

Used in Pharmaceutical Industry:
Benazepril is used as an antihypertensive agent for the treatment of high blood pressure. It functions by inhibiting the angiotensin-converting enzyme, which in turn leads to the relaxation of blood vessels and a decrease in blood volume. This dual action results in a reduction of blood pressure, making it a valuable medication for managing hypertension.
Additionally, Benazepril is often prescribed in combination with other medications to enhance its therapeutic effects and improve patient outcomes. It is important for patients to follow the dosage instructions provided by a healthcare professional and to be aware of potential side effects and drug interactions to ensure safe and effective use of the medication.

Upstream product

• 63-91-2 L-phenylalanine 
• 98807-38-6 Z-L-Val-O-COOMe 
• 1456-03-7 N-methoxycarbonyl-L-phenylalanine-p-nitrophenyl ester 
• 70148-11-7 N-Methoxycarbonylphenylalanin-p-nitrophenylester 
• 79-22-1 methyl chloroformate 
• 63-91-2 L-phenylalanine 

Downstream Products

• 41844-71-7 methyl (S)-2-methoxycarbonylamino-3-phenyl-propionate 
• 1020082-42-1 C₁₁H₁₃N₅O₃ 
• 1218815-47-4 (S)-2-methoxycarbonylamino-3-phenyl-propionic acid (R)-2-isopropyl-2,3-dimethyl-4-oxo-imidazolidin-1-yl ester 
• 63-91-2 L-phenylalanine 
• 133230-78-1 S₁-L-Phe-L-His-OMe 
• 133230-89-4 S₁-L-Phe-L-His-OH 
• 1008510-37-9 4-{(S)-2-[(S)-2-(methoxycarbonylamino)-3-phenylpropanamido]-2-[2-(thiophen-2-yl)thiazol-4-yl]ethyl}phenylsulfamic acid 

Relevant academic research and scientific papers

SMALL MOLECULE ACTIVATORS OF TIE-2

Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for vascular disorders that can include, for example, retinopathies, ocular edema, and ocular neovascularization.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to methods for making compounds useful in the treatment of Hepatitis C virus (HCV) infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) or Formula (II) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C Virus Inhibitors

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.